Project Details
Description
AURIGA is designed to collect data from routine clinical practice on the effectiveness and utilization of intravitreal aflibercept in the treatment of visual impairment due to diabetic macular edema (DME) or macula edema secondary to retinal vein occlusion (RVO).
The primary objective of this observational study (OS) is to evaluate the effectiveness of intravitreal aflibercept in 4 cohorts (with/without prior treatment in DME or macular edema secondary to RVO) in each of the participating countries.
Additionally, utilization and treatment regimens in routine clinical practice will be described.
Health care resources and services as well as health out-comes related to vision loss will be evaluated based on information collected using the AURIGA patient questionnaires.
The primary objective of this observational study (OS) is to evaluate the effectiveness of intravitreal aflibercept in 4 cohorts (with/without prior treatment in DME or macular edema secondary to RVO) in each of the participating countries.
Additionally, utilization and treatment regimens in routine clinical practice will be described.
Health care resources and services as well as health out-comes related to vision loss will be evaluated based on information collected using the AURIGA patient questionnaires.
| Acronym | AURIGA |
|---|---|
| Status | Finished |
| Effective start/end date | 24/11/17 → 17/12/21 |
Collaborative partners
- Ministry of Health and Prevention
- Bayer (lead)
- Regeneron Pharmaceuticals, Inc.
Keywords
- Macular Degeneration
- Retinal Degeneration
- Retinal Diseases
- Eye Diseases
- Venous Thrombosis
- Thrombosis
- Embolism and Thrombosis
- Vascular Diseases
- Cardiovascular Diseases
- Macular Edema
- Retina Vein Occlusion
- Edema
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Physiological Effects of Drugs
- Growth Inhibitors
- Antineoplastic Agents
- Aflibercept
- Diabetes
- Diabetic Retinopathy
- Diabetic Macular Edema
- Macular edema secondary to retinal vein occlusion
- Intravitreal anti-VEGF (vascular endothelial growth factor)
- VEGF inhibitor
- Real World Data
- Treatment Pattern
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.